Idexx Laboratories (IDXX) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] IDEXX Laboratories Inc (IDXX) 3-Minute Overview > **💡 One-Sentence Summary** > > Simply put, IDEXX is a high-quality animal health diagnostics company that sells essential testing tools to veterinarians, and the market is willing to pay a premium because the business is consistently profitable, sticky, and still growing. > **📍 Basic Profile** > > Market Cap **$44.7 billion** · Health Care · NASDAQ NMS - GLOBAL MARKET · Price **$563.12** > **⚡ 3 Things You Should Know** > > 1. 💰 Premium-quality business: IDEXX’s margins are excellent for a diagnostics company, with **61.8% gross margin** and **24.6% net margin**. In other words, this is not just growing revenue—it’s converting a lot of that revenue into real earnings. > > 2. 📈 Growth is solid, not flashy: Revenue has grown around **8.5%–9.7%** over 3–5 years, while EPS grew much faster at **14%–18%**. That usually means management is executing well and getting more efficient, but it also tells you this is more of a compounding quality story than a hypergrowth one. > > 3. 🏷️ Still priced for excellence: Even after pulling back from its 52-week high, the stock trades at about **42.2x earnings**, which is expensive for a company growing revenue high-single digits. Basically, the market is assuming IDEXX can keep delivering dependable growth with very few mistakes. > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin 24.62%, well above typical medtech/diagnostics levels | > | Growth Rate | Steady📈 | 3-year revenue growth 8.52%, EPS growth 17.66% | > | Financial Health | Healthy💚 | Debt-to-equity 52.81%, interest coverage 34.07x | > | Valuation | Pricey | PE 42.21x | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** IDEXX sells diagnostic instruments, consumables, software, and lab services to veterinarians, making money through a mix of recurring testing volume and equipment-driven ecosystem lock-in. **Revenue Breakdown:** | Business | Share | Trend | Comment | |----------|-------|-------|---------| | Companion animal diagnostics ecosystem | [Data unavailable] | ↑ | Likely the core engine; recurring tests usually create sticky revenue once clinics adopt IDEXX systems | | Other diagnostics / software / lab-related services | [Data unavailable] | → | Supports the main franchise, but detailed segment split was not provided | **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 61.8% | Top tier | Strong pricing power and a favorable mix of consumables/services | | Net Margin | 24.62% | Top tier | Shows this business scales well and keeps a meaningful share of revenue as profit | | ROE | 69.78% | Excellent>20% | Extremely high, though likely helped by capital structure and buybacks, so don’t read it as pure operating magic alone | --- #### 📈 How's the Growth? **Growth Assessment:** Steady Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth | 8.52% (3Y CAGR) | [Data unavailable] | Stable | | Profit Growth | 17.66% (EPS 3Y CAGR) | [Data unavailable] | Stronger than revenue | **Growth Quality:** > What’s interesting is that earnings have been growing much faster than revenue. That usually points to a healthy mix of operating leverage, buybacks, and disciplined execution rather than low-quality “growth at all costs.” The flip side: when a stock is valued this richly, even solid growth can disappoint if it isn’t accelerating. --- #### 💰 Financial Health Check **One Sentence:** This looks like a company with strong income, manageable debt, and no obvious balance-sheet stress—but not a huge liquidity cushion either. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt Ratio | 52.81% (using debt-to-equity as reference) | <60% safe | ✅Safe | | Current Ratio | 1.23 | >1.5 healthy | ⚠️Tight | | Cash Flow | Positive (cash flow/share $11.16) | >0 | ✅Positive | **Worth noting:** interest coverage of **34.07x** is very reassuring. So while short-term liquidity ratios are only okay, the company is generating enough earnings to make debt look manageable. --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $465.00 - 52-Week High: $769.98 - Current: $563.12, **in the lower-middle of the range** | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | ●(32.2% position) | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 42.21x | [Data unavailable] | [Data unavailable] | | vs Peers | PE 42.21x | [Data unavailable] | Likely above broad healthcare averages, but exact peer baseline not provided | **What the Current Valuation is Betting On:** > Basically, the market is betting that IDEXX remains a “quality compounder”: steady clinic demand, recurring testing revenue, new product wins like cancer diagnostics, and continued earnings growth without major margin erosion. If that story holds, the premium can persist. If growth slips into mid-single digits for too long, the multiple could compress. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | 2026-04 | Analysts focused on upcoming Q1 earnings and potential beat | Neutral/Positive — expectations remain constructive, which supports sentiment but also raises the bar | | 2026-04 | IDEXX launched canine cancer detection panel in the UK | Positive — expands innovation story and could deepen its diagnostics moat in companion animal health | | 2026-04 | Stock received a Buy upgrade / valuation debate resurfaced | Mixed — sentiment improved, but repeated “value” discussions suggest investors remain sensitive to its premium multiple | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Gross Margin | 61.8% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | Net Margin | 24.62% | [Data unavailable] | [Data unavailable] | [Data unavailable] | | ROE | 69.78% | [Data unavailable] | [Data unavailable] | [Data unavailable] | **Growth Trends:** | Metric | This Year | Last Year | Year Before | 3-Year Trend | |--------|-----------|-----------|-------------|--------------| | Revenue Growth | 8.52% (3Y CAGR) | [Data unavailable] | [Data unavailable] | ↑ | | Profit Growth | 17.66% (EPS 3Y CAGR) | [Data unavailable] | [Data unavailable] | ↑ | | EPS Growth | 17.66% (3Y CAGR) | [Data unavailable] | [Data unavailable] | ↑ | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | 2025-12-31 | $2.99 | $3.08 | +3.12% Beat 😀 | | 2025-09-30 | $3.19 | $3.40 | +6.47% Beat 😀 | | 2025-06-30 | $3.37 | $3.63 | +7.81% Beat 😀 | | 2025-03-31 | $2.91 | $2.96 | +1.72% Beat 😀 | **Earnings Trend Interpretation:** Four straight beats usually tell you management guides conservatively or executes very reliably—either way, the business is earning trust. The catch is that reliable beats often get “priced in,” so the stock may need continued outperformance to move meaningfully higher. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy/Buy | 15 firms | 65.2% | | Hold | 8 firms | 34.8% | | Sell | 0 firms | 0.0% | **Target Price:** [Data unavailable] ~ [Data unavailable] (Median [Data unavailable]) **vs Current Price:** [Data unavailable] **Insider Activity:** Net **selling** in past 3 months based on disclosed share changes > Insider selling here doesn’t automatically mean something is wrong—senior executives often sell for diversification or compensation-related reasons. But what you might care about is that there’s not much broad, aggressive open-market buying to signal that management sees the stock as obviously cheap. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **Valuation Risk:** The stock trades at **42.2x earnings** despite revenue growth in the high-single digits → If growth cools even a bit, the share price could react more sharply than the business fundamentals. 2. **Execution Risk:** Premium multiples require consistent earnings beats and product adoption → If a quarter misses expectations or instrument placements slow, sentiment could reset fast. 3. **Demand Sensitivity / Vet Spending Risk:** IDEXX is tied to animal healthcare activity and clinic testing volumes → If pet-owner spending weakens or vet clinic traffic softens, growth could decelerate. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** IDEXX is a high-quality veterinary diagnostics franchise with a sticky, recurring-revenue model. > > **Key strength:** Its margins, cash generation, and earnings consistency suggest a very well-run business with real competitive advantages. > > **Key risk:** The stock is still expensive enough that “good” results may not be enough—investors are paying for near-excellent execution. --- > **🔍 Want to Learn More?** > > • Want to know if this company has a strong moat? → Try【Buffett Mode】for deeper analysis > > • Want to check for hidden landmines? → Try【Muddy Mode】for risk screening > > • Is this a growth stock? Want to calculate if it's worth the bet? → Try【Musk Mode】for analysis